Infection of the biliary tract during palliative drainage in patients with hilar malignant jaundice

Authors

  • Ya.M. Susak Bogomolets National Medical University, Kyiv, Ukraine
  • R.Ya. Palitsa National Military Clinical Center “CMCH”, Kyiv, Ukraine
  • L.Yu. Markulan Bogomolets National Medical University, Kyiv, Ukraine
  • M.V. Maksуmenko Bogomolets National Medical University, Kyiv, Ukraine

DOI:

https://doi.org/10.22141/2224-0586.17.2.2021.230653

Keywords:

obstructive jaundice, Klatskin tumor, external-internal suprapapillary biliary drainage, percutaneous transhepatic biliary drainage, cholangitis, life expectancy

Abstract

Background. Hilar malignant biliary obstruction in about 80 % of patients is not subject to radical treatment. Percutaneous transhepatic biliary drainage (PTBD) eliminates jaundice syndrome but is associated with bile loss. External-internal drainage is intended to eliminate this disadvantage, however, the balance between its benefits and the risk of complications, in particular cholangitis, has not yet been determined. The aim was to compare the rate of cholangitis and survival after percutaneous transhepatic biliary drainage and external-internal suprapapillary drainage treatment in patients with hilar malignant jaundice. Materials and methods. Fifty patients with hilar malignant jaundice were prospectively examined. Patients who underwent percutaneous transhepatic biliary drainage were included in the PTBD group (n = 24); patients who underwent external-internal suprapapillary biliary drainage (EISBD) treatment were included in the EISBD group (n = 26). The endpoints of the study were the rate of cholangitis, cholangitis duration index (number of cholangitis-days per 100 patient-days in a group), and cumulative survival. Results. Cholangitis during the entire follow-up period occurred in 7 (14.0 %) patients: in 3 (11.5 %) patients in the EISBD group, in 4 (16.7 %) patients in the PTBD group; p = 0.602. Taking into account the census data (patients who died during this period), the difference in the cumulative frequency of cholangitis was more significant (25.6 % in the EISBD group, 49.1 % in the PTBD group); p = 0.142. The average time of the onset of cholangitis from the beginning of the operation was 68.8 ± 14.7 days in the PTBD group, 90.7 ± 42.0 days in the EISBD group; p = 0.601. In the EISBD group, the cholangitis duration index was less than in the PTBD group: 0.46 versus 1.4 cholangitis-days per 100 patient-days, respectively, p = 0.001. Patients of the EISBD group had a greater cumulative survival rate compared with the PTBD group: the median survival was 90 days (95% CI: 70.0–109.9 days) and 75 days (95% CI: 51.1–98.9 days), respectively; p = 0.033. Conclusions. For palliative management of hilar malignant jaundice, EISBD treatment should be the priority over PTBD treatment.

References

Moole H., Bechtold M.L., Forcione D., Puli S.R. A meta-ana­lysis and systematic review: success of endoscopic ultrasound guided biliarystenting in patients with inoperable malignant biliary strictures and a failed ERCP. Medicine. 2017. 96. e5154. PMID: 28099327.

Jarnagin W.R., Fong Y., DeMatteo R.P. et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann. Surg. 2001. 234(4). 507-517. doi: 10.1097/00000658-200110000-00010.

Parsi M.A. Common controversies in management of biliary strictures. World J. Gastroenterol. 2017. 23(7). 1119-1124. doi: 10.3748/wjg.v23.i7.1119.

Covey A.M., Brown K.T. Percutaneous transhepatic biliary drainage. Tech. Vasc. Interv. Radiol. 2008. 11(1). 14-20. doi: 10.1053/j.tvir.2008.05.003.

Vandenabeele L.A.M., Dhondt E., Geboes K.P., Defreyne L. Percutaneous stenting in malignant biliary obstruction caused by metastatic disease: clinical outcome and prediction of survival accor­ding to tumor type and further therapeutic options. Acta Gastroenterol. Belg. 2017. 80(2). 249-255. PMID: 29560690.

Sellier F., Bories E., Sibertin-Blanc C. et al. Clinical outcome after biliary drainage for metastatic colorectal cancer: survival analysis and prognostic factors. Dig. Liver Dis. 2017. 50(2). 189-194. DOI: 10.1016/j.dld.2017.09.121.

Fong Z.V., Brownlee S.A., Qadan M., Tanabe K.K. The Clinical Management of Cholangiocarcinoma in the United States and Europe: A Comprehensive and Evidence-Based Comparison of Guidelines. Ann. Surg. Oncol. 2021 Mar 1. doi: 10.1245/s10434-021-09671-y.

Soares K.C., Kamel I., Cosgrove D.P. et al. Hilar cholangiocarcinoma: diagnosis, treatment options, and management. Hepatobil. Surg. Nutr. 2014. 3. 18-34. PMID: 24696835.

Tian X., Zhang Z., Li W. Internal drainage versus external drainage in palliation of malignant biliary obstruction: a meta-analysis and systematic review. Arch. Med. Sci. 2020. 16(4). 752-763. doi: 10.5114/aoms.2020.94160.

Riaz A., Pinkard J.P., Salem R., Lewandowski R.J. Percutaneous management of malignant biliary disease. J. Surg. Oncol. 2019. 120(1). 45-56. doi: 10.1002/jso.25471.

Mayhew D., Mendonca V., Murthy B.V.S. A review of ASA physical status — historical perspectives and modern developments. Anaesthesia. 2019. 74. 373-9. PMID: 30648259.

Telford J.J., Carr-Locke D.L., Baron T.H., Poneros J.M., Bounds B.C., Kelsey P.B. et al. A randomized trial comparing uncovered and partially covered self-expandable metal stents in the palliation of distal malignant biliary obstruction. Gastrointest. Endosc. 2010. 72. 907-14. PMID: 21034891.

Yu H., Yuanyuan S., Guo Z., Xing W., Si T., Guo X., Liu F. Multifactorial analysis of biliary infection after percutaneous transhepatic biliary drainage treatment of malignant biliary obstruction. J. Cancer Res. Ther. 2018. 14(7). 1503-1508. doi: 10.4103/jcrt.JCRT_256_18.

Chandrashekhara S.H., Gamanagatti S., Singh A., Bhatnagar S. Current Status of Percutaneous Transhepatic Biliary Drainage in Palliation of Malignant Obstructive Jaundice: A Review Indian J. Palliat. Care. 2016. 22(4). 378-387. DOI: 10.4103/0973-1075.191746.

Liver Cancer Study Group of Japan. General rules for the clinical and pathological study of primary liver cancer, 2nd English edition. Tokyo, Japan: Kanehara, 2003.

Nishio H., Nagino M., Oda K., Ebata T., Arai T., Nimura Y. TNM classification for perihilar cholangiocarcinoma: comparison between 5th and 6th editions of the AJCC/UICC staging system. Langenbecks Arch. Surg. 2005. 390(4). 319-27. doi: 10.1007/s00423-005-0561-8.

Lesmana C.R., Gani R.A., Lesmana L.A. Non-alcoholic fatty pancreas disease, pancreatic cancer, and impact of endoscopic ultrasound examination on screening and surveillance. EMJ Gastroenterol. 2017. 6(1). 69-74. doi: 10.1002/jgh3.12032.

Bridgewater J.A., Goodman K.A., Kalyan A., Mulcahy M.F. Biliary Tract Cancer: Epidemiology, Radiotherapy, and Molecular Profiling. American Society of Clinical Oncology Educational Book. 2016. 35(36). e194-203. doi: 10.1200/EDBK_160831.

Bosman Frank T. “Chapter Chapter 5.6: Liver cancer”. World Cancer Report the International Agency for Research on Cancer, World Health Organization. Chapter 5.6. 2014. ISBN 978-92-832-0443-5.

De Jong M.C., Marques H., Clary B.M. et al. The impact of portal vein resection on outcomes for hilar cholangiocarcinoma: a multi-institutional analysis of 305 cases. Cancer. 2012. 118. 4737-47. Available at: https://onlinelibrary.wiley.com/doi/epdf/ 10.1002/cncr.27492.

Covey A.M., Brown K.T. Percutaneous transhepatic biliary drainage. Tech. Vasc. Interv. Radiol. 2008. 11(1). 14-20. doi: 10.1053/j.tvir.2008.05.003.

Lorenz J.M. Management of Malignant Biliary Obstruction. Semin. Intervent. Radiol. 2016. 33(4). 259-267. doi: 10.1055/s-0036-1592330.

Boulay B.R., Birg A. Malignant biliary obstruction: From palliation to treatment. World J. Gastrointest. Oncol. 2016. 8. 498-508.

Kurniawan J., Hasan I., Gani R.A. et al. Mortality-related factors in patients with malignant obstructive jaundice. Acta Med. Indones. 2016. 48(4). 282-8. PMID: 28143989.

Sabarudin A., Gani R.A., Abdullah M., Rumende C.M. Changes in tumor necrosis factor alpha and interleukin 6 levels in patients with obstructive jaundice due to pancreatobiliary cancer who underwent biliary drainage. Indones J. Gastroenterol. Hepatol. Dig. Endosc. 2016. 17(2). 93-8.

Walter T., Ho C.S., Horgan A.M. et al. Endoscopic or percutaneous biliary drainage for Klatskin tumors? J. Vasc. Interv. Radiol. 2013. 24(1). 113-121. PMID: 23182938.

Guidi M.A., Curvale C., Viscardi J. et al. Hilar bile duct tumors: endoscopic or percutaneous drainage? A prospective analysis. Rev. Esp. Enferm. Dig. 2015. 107. 488-494. doi: 10.17235/reed.2015.3704/2015.

Guibaud I., Bret P.M., Reinhold C., Atri M., Barkun A.N. Bile duct obstruction and choledocholithiasis: diagnosis with MR cholangiography. Radiology. 1995. 197. 109-115. doi: 10.1148/radiology.197.1.7568807.

Vagholkar K. Obstructive jaundice: understanding the pathophysiology. International Journal of Surgery and Medicine. 2020. 6(4). 26-31.

Sano T., Ajiki T., Takeyama Y., Kuroda Y. Internal biliary drainage improves decreased number of gut mucosal T lymphocyte and MAdCAM-1 expression in jaundiced rats. Surgery. 2004. 136. 693-699.

Assimakopoulos S.F., Scopa C.D., Vagianos C.E. Pathophysilogy of increased intestinal permeability in obstructive jaundice. World J. Gastroenterol. 2007. 13. 6458-6464.

Ho C.S., Warkentin A.E. Evidence-based decompression in malignant biliary obstruction. Korean J. Radiol. 2012. 13(Suppl. 1). S56-S61. doi: 10.3348/kjr.2012.13.S1.S56.

Manwong M., Songserm N., Promthet S. et al. Risk factors for cholangiocarcinoma in the lower part of Northeast Thailand: a hospital-based caseocontrol study. Asian Pac. J. Prev. 2013. 14. 5953-6. DOI: 10.7314/apjcp.2013.14.10.5953.

Xu C., Lv P.H., Huang X.E., Sun L., Wang S.X., Wang F.A. Internal-external percutaneous transhepatic biliary drainage for patients with malignant obstructive jaundice. Asian Pac. J. Cancer Prev. 2014. 15(21). 9391-4. doi: 10.7314/apjcp.2014.15.21.9391.

Barkay O., Khashab M., Al-Haddad M., Fogel E.L. Minimizing complications in pancreaticobiliary endoscopy. Current Gastroenterology Reports. 2009. 11(2). 134-141. doi: 10.1007/s11894-009-0021-7.

Published

2021-05-24

Issue

Section

Original Researches